Cocrystals of hydrochlorothiazide: Solubility and diffusion/permeability enhancements through drug-coformer interactions

Molecular Pharmaceutics

Volumn 12, Issue 5, 2015, Pages 1615-1622

  Sanphui, Palash ^a   Devi, V Kusum ^b   Clara, Deepa ^b   Malviya, Nidhi ^b   Ganguly, Somnath ^a   Desiraju, Gautam R ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

^b AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

cocrystal; diffusion; flux; heterosynthons; permeability; solubility

Indexed keywords

4 AMINOBENZOIC ACID; HYDROCHLOROTHIAZIDE; NICOTINAMIDE; NICOTINIC ACID; RESORCINOL; SULFONAMIDE; AMIDE; RESORCINOL DERIVATIVE; SUCCINAMIDE; SUCCINIC ACID DERIVATIVE;

ARTICLE; CRYSTAL; CRYSTAL STRUCTURE; DRUG ABSORPTION; DRUG DIFFUSION; DRUG SOLUBILITY; GRINDING; HYDROPHOBICITY; MEMBRANE PERMEABILITY; PH; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; STEADY STATE; SURFACE PROPERTY; X RAY DIFFRACTION; CHEMISTRY; CRYSTALLIZATION; DIFFUSION; PERMEABILITY; SOLUBILITY;

4-AMINOBENZOIC ACID; AMIDES; CRYSTALLIZATION; DIFFUSION; HYDROCHLOROTHIAZIDE; NIACIN; NIACINAMIDE; PERMEABILITY; RESORCINOLS; SOLUBILITY; SUCCINATES;

EID: 84929174916     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00020     Document Type: Article

References (38)

1. Dahan, A.; Hoffman, A. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs J. Controlled Release 2008, 129, 1-10
2. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 2001, 46, 3-26
3. Lipinski, C. A.; Lombardo, F. B.; Dominy, W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25
4. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12, 413-420
5. Harde, H.; Das, M.; Jain, S. Solid lipid nanoparticles: an oral bioavailability enhancer vehicle Expert Opin. Drug Delivery 2011, 8, 1407-1424
6. Desiraju, G. R. Crystal engineering: from molecule to crystal J. Am. Chem. Soc. 2013, 135, 9952-9967
7. Pharmaceutical Salts and Co-crystals; Wouters, J.; Quéré, L., Eds.; Royal Society of Chemistry: Cambridge, 2011.
8. Almarsson, Ö.; Zaworotko, M. J. Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines? Chem. Commun. 2004, 1889-1896
9. Yan, Y.; Chen, J.-M.; Lu, T.-B. Simultaneously enhancing the solubility and permeability of acyclovir by crystal engineering approach CrystEngComm 2013, 15, 6457-6460
10. Karki, S.; Friščić, T.; Fábián, L.; Laity, P. R.; Day, G. M.; Jones, W. Improving mechanical properties of crystalline solids by cocrystal formation: new compressible forms of paracetamol Adv. Mater. 2009, 21, 3905-3909
11. Smith, A. J.; Kavuru, P.; Wojtas, L.; Zaworotko, M. J.; Shytle, R. D. Cocrystals of quercetin with improved solubility and oral bioavailability Mol. Pharmaceutics 2011, 8, 1867-1876
12. Chen, J.; Wang, Z.; Chuan-Bin, W.; Li, S.; Lu, T. Crystal engineering approach to improve the solubility of mebendazole CrystEngComm 2012, 14, 6221-6229
13. Babu, N. J.; Sanphui, P.; Nangia, A. Crystal engineering of stable temozolomide cocrystals Chem.-Asian J. 2012, 7, 2274-2285
14. Good, D. J.; Rodríguez-Hornedo, N. Solubility advantage of pharmaceutical cocrystals Cryst. Growth Des. 2009, 9, 2252-2264
15. Sanphui, P.; Goud, N. R.; Khandavilli, U. B. R.; Nangia, A. Fast dissolving curcumin cocrystals Cryst. Growth Des. 2011, 11, 4135-4145
16. McNamara, D. P.; Childs, S. L.; Giordano, J.; Iarriccio, A.; Cassidy, J.; Shet, M. S.; Mannion, R.; O'Donnell, E.; Park, A. Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API Pharm. Res. 2006, 23, 1888-1897
17. Ren, C.; Fang, L.; Li, T.; Wang, M.; Zhao, L.; He, Z. Effect of permeation enhancers and organic acids on the skin permeation of indapamide Int. J. Pharm. 2008, 350, 43-47
18. Masuda, T.; Yoshihashi, Y.; Yonemochi, E.; Fujii, K.; Uekusa, H.; Terada, K. Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir Int. J. Pharm. 2012, 422, 160-169
19. Sanphui, P.; Tothadi, T.; Ganguly, S.; Desiraju, G. R. Salts and cocrystals of sildenafil with dicarboxylic acids: solubility and pharmacokinetic advantage of the glutarate salt Mol. Pharmaceutics 2013, 10, 4687-4697
20. McCall, A. L.; Millington, W. R.; Wurtman, R. J. Blood-brain barrier transport of caffeine: dose-related restriction of adenine transport Life Sci. 1982, 31, 2709-2715
21. Agus, D. B.; Gambhir, S. S.; Pardridge, W. M.; Spielholz, C.; Baselga, J.; Vera, J. C.; Golde, D. W. Vitamin C crosses the blood-brain barrier in the oxidized form through the glucose transporters J. Clin. Invest. 1997, 100, 2842-2848
22. Dupont, L.; Dideberg, O. Structure cristalline de l'hydrochlorothiazide Acta Crystallogr. 1972, B28, 2340-2347
23. Sanphui, P.; Rajput, L. Tuning solubility and stability of hydrochlorothiazide co-crystal Acta Crystallogr. 2014, B70, 81-90
24. Pade, V.; Stavchansky, S. Link between drug absorption solubility and permeability measurements in Caco-2 cells J. Pharm. Sci. 1998, 87, 1604-1607
25. Avdeef, A.; Bendels, S.; Di, L.; Faller, B.; Kansy, M.; Sugano, K.; Yamauchi, Y. PAMPA-critical factors for better predictions of absorption J. Pharm. Sci. 2007, 96, 2893-2909
26. Ruel, J. A.; Avdeef, A. Absorption screening using the PAMPA approach Methods Pharmacol. Toxicol. 2004, 37-64
27. Artursson, P.; Karlsson, J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells Biochem. Biophys. Res. Commun. 1991, 175, 880-885
28. Franz, T. J. The finite dose technique as a valid in vitro model for the study of percutaneous absorption in man Curr. Probl. Dermatol. 1978, 7, 58-68
29. Ng, S.-F.; Rouse, J.; Sanderson, D.; Eccleston, G. A comparative study of transmembrane diffusion and permeation of ibuprofen across synthetic membranes using Franz diffusion cells Pharmaceutics 2010, 2, 209-223
30. Glomme, A.; Marz, J.; Dressman, J. B. Comparison of a miniaturized shake-flask solubility method with automated potentiometric acid/base titrations and calculated solubilities J. Pharm. Sci. 2005, 94, 1-16
31. Dahan, A.; Miller, J. M.; Hoffman, A.; Amidon, G. E.; Amidon, G. L. The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone J. Pharm. Sci. 2010, 99, 2739-2749
32. Miller, J. M.; Dahan, A. Oral delivery of lipophilic drugs: the tradeoff between solubility increase and permeability decrease when using cyclodextrin-based formulations Int. J. Pharm. 2012, 430, 388-391
33. Molecular Biopharmaceutics: Aspects of Drug Characterisation, Drug Delivery and Dosage Form Evaluation; Brodin, B.; Steffansen, B.; Nielsen, C. U., Eds.; PharmaPress Ltd.: Chicago, IL, 2010; pp 135-151, Chapter 3.
34. Wu, C.; Bernet, L. Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system Pharm. Res. 2005, 22, 11-23
35. Sanphui, P.; Kumar, S. S.; Nangia, A. Pharmaceutical cocrystals of niclosamide Cryst. Growth Des. 2012, 12, 4588-4599
36. Bolla, G.; Sanphui, P.; Nangia, A. Solubility advantage of tenoxicam phenolic cocrystals compared to salts Cryst. Growth Des. 2013, 13, 1998-2003
37. Spackman, M. A.; McKinnon, J. J. Fingerprinting intermolecular interactions in molecular crystals CrystEngComm 2002, 4, 378-392
38. Spackman, M. A.; Jayatilaka, D. Hirshfeld surface analysis CrystEngComm 2009, 11, 19-32